KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Deferred Taxes (2018 - 2020)

Ionis Pharmaceuticals (IONS) has 3 years of Deferred Taxes data on record, last reported at $340.1 million in Q4 2020.

  • For Q4 2020, Deferred Taxes rose 10754.14% year-over-year to $340.1 million; the TTM value through Sep 2021 reached $340.1 million, up 22140.18%, while the annual FY2020 figure was $341.7 million, 37411.42% up from the prior year.
  • Deferred Taxes reached $340.1 million in Q4 2020 per IONS's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $340.1 million in Q4 2020 and bottomed at -$290.5 million in Q4 2018.
  • Average Deferred Taxes over 3 years is $5.8 million, with a median of $887000.0 recorded in 2019.
  • The widest YoY moves for Deferred Taxes: up 10754.14% in 2020, down 116.89% in 2020.
  • A 3-year view of Deferred Taxes shows it stood at -$290.5 million in 2018, then surged by 98.9% to -$3.2 million in 2019, then surged by 10754.14% to $340.1 million in 2020.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $340.1 million in Q4 2020, $1.5 million in Q3 2020, and $2.5 million in Q2 2020.